25882 Federal Register / Vol. 61, No. 101 / Thursday, May 23, 1996 / Notices

ATSDR MINIMAL RISK LEVELS (MRLS) FOR HAZARDOUS SUBSTANCES—Continued

[March 1996]

Substance name CAS No. Route Duration Value Factors End point

1,3-DI-CHLOROPROPENE.000542–75–6 INHALATION ............. INTERMEDIATE ........ 0.003 ppm ................. 100 Respiratory.

INHALATION ............. CHRONIC .................. 0.002 ppm ................. 100 Respiratory.

1,3-DI-NITRO-BENZENE 000099–65–0 ORAL ......................... ACUTE ...................... 0.008 mg/kg/day ........ 100 Reproductive.

ORAL ......................... INTERMEDIATE ........ 0.0005 mg/kg/day ...... 1000 Hematological.

1,4-DI-CHLORO-BENZENE.000106–46–7 INHALATION ............. INTERMEDIATE ........ 0.2 ppm ..................... 100 Hepatic.

ORAL ......................... INTERMEDIATE ........ 0.1 mg/kg/day ............ 100 Hepatic.

1-METHYLNAPHTHALENE.000090–12–0 ORAL ......................... CHRONIC .................. 0.07 mg/kg/day .......... 1000 Respiratory.

2,3,4,7,8-PENTACHLORO-DI-BENZOFURAN.057117–31–4 ORAL ......................... ACUTE ...................... 0.000001 mg/kg/day 3000 Immunological.

ORAL ......................... INTERMEDIATE ........ 0.00000003 mg/kg/

day.

3000 Hepatic.

2,3,7,8-TETRACHLORO-DIBENZOP-DIOXIN.001746–01–6 ORAL ......................... ACUTE ...................... 0.0000001 mg/kg/day 1000 Hepatic.

ORAL ......................... INTERMEDIATE ........ 0.000000001 mg/kg/

day.

1000 Reproductive.

ORAL ......................... CHRONIC .................. 0.000000001 mg/kg/

day.

1000 Reproductive.

2,4,6-TRI-CHLOROPHENOL.000088–06–2 ORAL ......................... INTERMEDIATE ........ 0.04 mg/kg/day .......... 100 Reproductive.

2,4,6-TRI-NITROTOLUENE.000118–96–7 ORAL ......................... INTERMEDIATE ........ 0.0005 mg/kg/day ...... 1000 Hepatic.

2,4-DI-NITRO-PHENOL 000051–28–5 ORAL ......................... ACUTE ...................... 0.01 mg/kg/day .......... 100 Body Weight.

2,4-DI-NITRO-TOLUENE 000121–14–2 ORAL ......................... ACUTE ...................... 0.06 mg/kg/day .......... 1000 Hematological.

ORAL ......................... INTERMEDIATE ........ 0.05 mg/kg/day .......... 100 Reproductive.

ORAL ......................... CHRONIC .................. 0.002 mg/kg/day ........ 100 Hematological.

2,6-DI-NITRO-TOLUENE 000606–20–2 ORAL ......................... INTERMEDIATE ........ 0.04 mg/kg/day .......... 100 Neurological.

4,4°-METHYL-ENE-BIS

(2-CHLOROANILINE).

000101–14–4 ORAL ......................... CHRONIC .................. 0.003 mg/kg/day ........ 3000 Hepatic.

4,6-DI-NITRO-O-CRESOL.000534–52–1 ORAL ......................... ACUTE ...................... 0.004 mg/kg/day ........ 100 Neurological.

ORAL ......................... INTERMEDIATE ........ 0.004 mg/kg/day ........ 100 Neurological.

[FR Doc. 96–12991 Filed 5–22–96; 8:45 am]

BILLING CODE 4163–70–P

Food and Drug Administration

Advisory Committee; Science Board to

the Food and Drug Administration;

Formation of a Subcommittee

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

formation of a subcommittee of the

Science Board to the Food and Drug

Administration (Science Board). This

subcommittee has been established to

address issues related to science and

research in FDA. The subcommittee’s

preliminary recommendations will be

presented to the FDA Science Board for

full public discussion at a future

Science Board meeting.

FOR FURTHER INFORMATION CONTACT:

Susan A. Homire, Office of Science

(HF–33), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–3340.

SUPPLEMENTARY INFORMATION: The Food

and Drug Administration (FDA) is

announcing the formation of a

subcommittee to the Science Board to

the Food and Drug Administration. This

subcommittee has been established to

address issues related to science and

research in FDA. The subcommittee will

meet several times over the next 6 to 9

months to develop preliminary

recommendations for the Science Board

on a process for review of research

programs within FDA. During this

period there will be opportunities for

public comment; these opportunities

will be announced in the Federal

Register at least 15 days prior to each

scheduled public meeting. The

subcommittee’s preliminary

recommendations will be presented to

the Science Board for full public

discussion at a future Science Board

meeting. This notice is issued under the

Federal Advisory Committee Act of

October 6, 1972 (Pub. L. 92–463 (5

U.S.C. app. 2)).

Dated: May 16, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–12877 Filed 5–22–96; 8:45 am]

BILLING CODE 4160–01–F

Investigational Biological Product

Trials; Procedure to Monitor Clinical

Hold Process; Meeting of Review

Committee and Request for

Submissions

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing a

meeting of the clinical hold review

committee, which reviews the clinical

hold orders that the Center for Biologics

Evaluation and Research (CBER) has

placed on certain investigational

biological product trials. FDA is inviting

any interested biological product

company to use this confidential

mechanism to submit to the committee

for its review the name and number of